StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where PRGO sits in our scored universe today on a single observational measurement. P85 means PRGO ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Finnhub hasn't published the next scheduled earnings date yet. The list typically populates 4–8 weeks before the call.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-07 | $12.21 | $11.72 | -4.01% | 2.7M |
| 05-08 | $11.78 | $11.71 | -0.59% | 2.5M |
| 05-11 | $11.84 | $11.07 | -6.50% | 2.6M |
| 05-12 | $11.02 | $11.12 | +0.91% | 2.9M |
| 05-13 | $11.11 | $10.91 | -1.80% | 2.3M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for PRGO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for PRGO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Each factor shows PRGO's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q1 2026 2026-03-28 | Annual 2025 2025-12-31 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 |
|---|---|---|---|---|
Revenue | $969.20M | $4.25B | $3.14B | $2.10B |
Operating Income | $-372.30M | $-1.12B | $164.90M | $92.30M |
Net Income | $-398.60M | $-1.43B | $-7.30M | $-8.40M |
EPS (Diluted) | $-2.87 | $-10.29 | $-0.05 | $-0.10 |
Total Assets | $7.98B | $8.54B | $10.08B | $10.09B |
Total Liabilities | $5.48B | $5.60B | $5.64B | $5.62B |
Cash & Equivalents | $357.20M | $531.60M | $432.10M | $454.20M |
Free Cash Flow OCF − CapEx | $-127.40M | $145.10M | $-3.50M | $-33.30M |
Shares Outstanding | 138.10M | 137.60M | 137.60M | 137.60M |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Press releases, AI summaries, and links to free transcript sources. Audio webcasts live on the issuer's IR site.
Press releases served direct from sec.gov. Stonvex doesn't host transcript bodies — these require the publisher's terms.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
What drives PRGO's price movement
Outperforming its sector. Watch for sector rotation and relative momentum shifts.
In-line with sector
Moderate news sensitivity
Moderate sentiment influence
Low volume impact — moves on other factors
Low flow signal — not institutional-driven
Not momentum-driven — mean-reverts quickly
DNA analysis is based on current factor scoring. Not investment advice.
Quiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.